For BRAF-mutant melanoma, lowered levels of extracellular vesicle-melanoma membrane-bound proteins such as LNGFR, MCAM, MCSP, and ERBB3 have been correlated with patient responses to BRAF/MEK inhibitors; however, further validation is required before these can be routinely implemented in clinical practice [50]. This evidence concerns the gene MCAM and melanoma.